CDK4 and breast carcinoma: According to NCCN Clinical Practice Guidelines 2021 for breast cancer, combined or single use of fulvestrant and/or CDK4/6 inhibitors have been recommended as the first-line or second-line therapeutic regimen for patients with tamoxifen treatment failure [27].